We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Faster Method for Detecting Bioterror Threats

By LabMedica International staff writers
Posted on 14 Nov 2012
A new technique that screens for pairs of affinity reagents that bind with target bacteria, toxins, or viruses could speed up detection of bioterror threats and the application of countermeasures.

Developed by researchers at the Texas Biomedical Research Institute (San Antonio, USA), the mandate of the stopgap test was to be able to detect an unknown bioterror threat within 48 hours using inexpensive and widely-available laboratory reagents, using the Marburgvirus as a model target. More...
The method was designed to serve as a possible response to an “Andromeda Strain” scenario, citing the Michael Crichton book and movie about a research team’s effort to rapidly investigate a deadly organism.

The new process screens for pairs of affinity reagents, molecular magnets that bind to and hold on to their targets. The pipeline was initially developed using llama antibodies as the affinity reagents to Clostridium botulinum neurotoxins. When the researchers were satisfied that the system was working, they created another stopgap test within days for Ebolavirus Zaire ebolavirus. Such rapid detection will enable countermeasures to be selected and utilized much faster than the current practice, which requires sophisticated, costly equipment to purify and analyze the affinity reagents that can take weeks to months. The new method was described in the November 5, 2012, issue of the Nature Publishing Group Scientific Reports.

“It had to be simple and self-contained as we eventually needed it to work in the spacesuit lab or hot zone. The great thing about this test pipeline is that it can be applied to almost any target of interest, including markers of diseases like cancer,” said coauthor Texas Biomed virologist Andrew Hayhurst, PhD. “Using crude extracts from E. coli, the workhorse bacterium of the biotechnology laboratory, the new route bypasses the need for purification and complex equipment, enabling screening to be performed in under an hour.”

C. botulinum neurotoxins and Ebolavirus are among a handful of threats now categorized as Tier 1 agents, presenting the greatest risk of deliberate misuse with the most significant potential for mass casualties or devastating effects to the economy, critical infrastructure, and public confidence.

Related Links:
Texas Biomedical Research Institute



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.